EZH2 as a Potential Target in Diffuse Large B Cell Lymphoma
Ari Melnick, MD, a professor of medicine at the Weill Cornell Medical College, discusses EZH2 and its potential as a target in diffuse large B cell lymphoma
Ari Melnick, MD, a professor of medicine at the Weill Cornell Medical College, discusses EZH2 and its potential as a target in diffuse large B cell lymphoma (DLBCL).
Clinical Pearls:
- EZH2 is an epigenetic modifier protein that forms part of the so-called polycomb complex 2 that was found to be highly expressed in DLBCL
- Studies have shown that EZH2 functions to suppress checkpoints that stops cells from dividing
- EZH2 is frequently mutated in the GCB-type DLBCL tumors and in follicular lymphomas, supercharging the protein
- The mutation adds three methyl groups to the tails of histone 3 lysine 27, which causes the repression of proliferation checkpoint regulatory genes and genes involved in the differentiation of B cells
- The supercharged EZH2 blocks the ability of germinal center B cells to differentiate, causing the cells to continue to divide
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
